tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Emergent BioSolutions Secures $30M BARDA Contract Extension

Story Highlights
  • Emergent BioSolutions received a $30 million contract modification from BARDA for CYFENDUS™.
  • The contract supports U.S. national security by ensuring anthrax vaccine availability through March 2026.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Emergent BioSolutions Secures $30M BARDA Contract Extension

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Emergent Biosolutions ( (EBS) ) has issued an announcement.

On August 29, 2025, Emergent BioSolutions received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply additional doses of CYFENDUS™, an anthrax vaccine. This contract, part of an ongoing agreement since 2016, underscores Emergent’s commitment to supporting U.S. national security priorities by ensuring the availability of medical countermeasures against anthrax threats. The deliveries are expected to start within the current calendar year and conclude by March 2026, highlighting Emergent’s strategic role in biodefense.

The most recent analyst rating on (EBS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Spark’s Take on EBS Stock

According to Spark, TipRanks’ AI Analyst, EBS is a Neutral.

Emergent Biosolutions’ overall stock score is driven by a strong valuation and positive earnings call sentiment, indicating potential for recovery. However, financial performance challenges and legal proceedings weigh on the score. Technical indicators show positive momentum, but caution is advised due to overbought signals.

To see Spark’s full report on EBS stock, click here.

More about Emergent Biosolutions

Emergent BioSolutions is a company focused on delivering protective and life-saving solutions for health threats such as smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies. The company has been operational for over 25 years, preparing those responsible for public health protection.

Average Trading Volume: 1,294,509

Technical Sentiment Signal: Buy

Current Market Cap: $407.1M

Find detailed analytics on EBS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1